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Whereas in younger patients diagnosed with acute myeloid leukemia (AML) treatment is straightforward and the goal is cure,
the optimal treatment decision for older adults remains highly controversial. Physicians need to determine whether palliation,
“something” beyond palliation, intensive therapy, or an investigational therapy is the most appropriate treatment option. This
requires understanding of the biology and risk proﬁle of the AML, clinical judgment in evaluating the functional status of the
patient, communication skills in understanding the patient’s wishes and social background, and medical expertise in available
therapies. The physician has to accurately inform the patient about (a) the unique biological considerations of his leukemia and
his prognosis; (b) the risks and beneﬁts of all available treatment options; (c) novel therapeutic approaches and how the patient
can get access to these treatments. Last but not least, he has to recommend a treatment. This paper tries to discuss each of these
issues.
1.Introduction
Elderly acute myeloid leukaemia (AML), generally deﬁned
as AML in a patient who is more than 60 years of age, is
a clinical entity distinct from the AML in younger adults
or children. Unlike in younger adults with AML in which
the treatment is straightforward and the goal is cure with
intensive chemotherapy, treatment decisions in elderly
patients with AML are diﬃcult and remain controversial.
Aggressive treatment necessitates hospitalization and
separation from family and home, has toxic and potentially
fatal side eﬀects, and is often ineﬀective. There are several
factors which inﬂuence the treatment decision process.
The wishes of patients and their families, performance
status, comorbidities, and other less well quantiﬁable
age-related health and social factors are important
determinants in the therapeutic decision. Undoubtedly,
the advice and inﬂuence of physicians has a major impact
on treatment decision making [1]. The physician needs
to determine whether palliation, “something” beyond
palliation, intensive therapy, or an investigational therapy
is the most appropriate treatment option. This requires
thorough understanding of the biology and risk proﬁle of
the AML, clinical judgment in evaluating the functional
status of the patient, communication skills in understanding
the patient’s wishes and social background, and medical
expertise and competence in available treatment options
and novel approaches. The physician has to give accurate
information to the patient about (1) the unique biological
considerations of his leukemia and his prognosis; (2) the
risks and beneﬁts of all available treatment options; (3) novel
therapeutic approaches and how the patient can get access
to these treatments. Last but not least he has to recommend
a treatment. This review tries to discuss each of these issues.
2. Features of AML in the Elderly
AML in the elderly has a grim prognosis. It is of paramount
importance to inform the patients and relatives that their
disease and their prognosis diﬀer from AML in younger
patients. The data of the American SEER-programme
(Surveillance, Epidemiology, and End result) report that
in comparison to younger patients who have a 30%–35%
chance of cure, only 5% of the elderly patients with AML2 Journal of Oncology
can be cured (http://www.seer.cancer.gov/). Retrospective
analyses from haematological centres all over the world and
analysis of insurance claims report a median survival that
ranges from a few weeks to 4 months irrespective of the
treatment given [2–4].
Why do older patients fare signiﬁcantly worse than their
younger counterparts? Old age is recognized as a risk factor
for both the two major causes of therapeutic failure in AML:
treatment related mortality (TRM) and resistance to therapy
[5,6].Olderindividualstoleratelesswellaggressivetherapies
due to poor performance status, presence of comorbid
disease, decreased ability of clearance of chemotherapy and
poor tolerance of systematic bacterial and fungal infections
[7]. On the other hand, the disease in older patients shows
anincreasedproportion ofunfavorablekaryotype(especially
abnormalities of chromosomes 5 and 7 or complex chro-
mosomal aberrations) [6, 7], the emergence of AML from
an antecedent haematological disorder (AHD) [7, 8], the
presence of dysplastic changes [6, 9], the frequent expression
of the multidrug resistance (MDR) phenotype [8] and the
involvement of more primitive progenitors in the leukemic
process [9], all of the above associated with increased
resistance to treatment. Recently, a study evaluating gene
expression proﬁling in leukemic samples of 170 elderly AML
patients identiﬁed subgroups of patients with distinct gene
expression signatures [10]. These subgroups also diﬀered in
terms of resistant disease, complete remission and leukemia
free survival rates, suggesting that gene expression proﬁling
may further shed light on biologic features contributing to
the resistance and the adverse prognosis of elderly AML [10].
3. CurrentAvailable Therapeutic Strategies:
Risks andBeneﬁts
Whereas in younger patients the goal of treatment is cure,
the optimal treatment decision for older adults with AML
remains highly controversial and is a major challenge for
clinicians treating these patients. The clinician has to choose
from at least four diﬀerent approaches: supportive care only,
less intensive chemotherapy, standard intensive chemother-
apy or oﬀering the patient an investigational therapy into a
controlled clinical trial [5, 11]. On the one hand, palliation
obviously oﬀers the patient no chance for cure. On the other
hand, reluctance towards more aggressive approaches relies
on the increased risk of TRM due to severe toxicity and
the increased costs due to prolonged hospitalization without
a clear beneﬁt for the patient regarding overall survival
[2, 7]. Further, early results from novel, investigational
agents are often promising, however, in many cases they are
not conﬁrmed by subsequent studies [5]. Finally, especially
in older patients, the beneﬁt has to be determined not
only with traditional measurements of outcomes but also
in terms of quality of life, control of symptoms, need
of transfusions and antibiotics, distance from haematology
institution, hospitalisation, and the feeling of independence.
The patients should be encouraged to deﬁne their treatment
goals, in this way actively participating in the decision
making process.
3.1.ElderlyAML:FitforIntensiveChemotherapyorPalliation?
Intensive chemotherapy in older AML patients is given with
the intent to achieve longer life expectancy and possibly
a cure. The intensive chemotherapy regime that is most
commonly used in elderly AML is the “3 + 7 regime” which
is also applied in younger AML patients and consists of
3d a y so fd a u n o r u b i c i n( 4 5 m g / m 2 per day) and 7 days
cytarabine (100–200mg/m2 per day) [7]. However, older
patients exhibit a poor chemotherapeutic tolerance with
early death rates ranging from 15% to 25% [5]. Further, the
CR rates of these patients are poor, ranging between 30%–
55%, these remissions are of short duration and a cure is
rarely observed [6]. However, those elderly AML patients
who succeed to achieve a CR require less hospitalization
and have a relatively good quality of life. In contrast to
intensive chemotherapy, palliative care does not aim to cure
but includes only supportive measures for the consequences
of bone marrow failure caused by AML and/or low dose
cytoreductive therapy. The median survival of the patient
treated with palliative measures is less than 4 months [2, 4].
Low dose cytarabine is able to induce CR in a fraction of
elderly AML patients [12, 13], but it can also induce long
lasting myelosuppression and its beneﬁcial eﬀect in terms
o fo v e r a l ls u r v i v a la sc o m p a r e dt ob e s ts u p p o r t i v ec a r ei s
observed only in the absence of adverse cytogenetics [12, 13].
A retrospective analysis of 2657 medicare beneﬁciaries
>65 years old with AML reﬂects the general attitude of
clinicians on the dilemma between palliation or intensive
chemotherapy: only 30% of these elderly patients received
any intravenous chemotherapy in the 2 years after diagnosis
(44% in ages 65–74 years, 24% in ages 75–84 years and 6%
in ages >85 years) [2]. Also, Whalin et al., reported on an
unselectedpatientpopulationwithAMLinnorthernSweden
that advanced age was a negative predictor for the likelihood
of referral to a centre where intensive chemotherapy could
be performed [14]. These data suggest that a considerable
number of elderly patients are actually oﬀered only palliative
care in routine practice. However, emerging evidence suggest
that chronological age alone is not adequate to guide the
available treatment options [5]. Instead, a “personalized”
treatment approach seems to emerge in elderly AML, where
therapeutic decisions are individualized based on stratiﬁ-
cation systems which include (1) the distinctive biologic
features of each patient’s leukemia as well as (2) eﬃcient
assessment of physical status and comorbidity.
First, the emergence over the last decade of unique
cytogenetic and molecular features with a major prognostic
impact has deﬁned distinct risk groups among the elderly
AML population with almost opposing responses to induc-
tion chemotherapy [15]: For instance, elderly patients with
favourable cytogenetics (e.g., t(8; 21), inv(16)/t(16; 16),
deﬁned as CBF AML) are probable candidates for intensive
chemotherapy due to the high response rates (CR = 88%)
reported [16]. In contrast, the likelihood of potential cure
with the same treatment is essentially impossible in AML
patients with complex or monosomal karyotypes (e.g., those
with −7) [5, 17] so as an investigational therapy or palliative
therapy is suggested to be oﬀered in these patients instead
of standard induction chemotherapy [18, 19]. Importantly,Journal of Oncology 3
in elderly AML patients with standard risk cytogenetics
treatment with intensive chemotherapy results in a median
overall survival of up to 12 months, whereas in the adverse
cytogenetic category median survival is only 2-3 months,
not diﬀerent from the median survival observed when
only best supportive care is oﬀered [15, 20, 21]. Also,
additional molecular aberrations within the “intermediate
risk” cytogenetic group of elderly AML, as the NPM1
mutation, are shown to provide prognostic information
[22, 23]. Importantly, in the absence of leukocytosis (WBC
< 50 × 109/L), delaying intensive treatment administration
in older AML patients does not seem to have a harmful
impact on their outcome regarding CR rates and sur-
vival, suggesting that in the elderly population one could
probably “wait” for cytogenetic and molecular results to
be available to deﬁnitively decide the treatment strategy
[24].
Second, individuals of the same age are an extremely
heterogeneous population, ranging from severely ill to
completely ambulatory [7]. Emerging evidence suggest that
in elderly AML patients who are extremely aged or have
a severely impaired performance status palliative therapy
should be preferred. In a retrospective analysis of 968 adults
with AML, the combination of a poor performance status
(>2-3 ECOG) and advanced age (>75 years) identiﬁed a
group of patients with a very high likelihood of dying within
30 days of the initiation of induction [25]. Similarly, in
another analysis of 998 elderly (>65 years) patients with
AML, a poor performance status (>3-4 ECOG) was identi-
ﬁed as a risk factor for 8-week mortality and shorter survival
[26]. Importantly, in the elderly AML patients with a high
level of comorbid disease as deﬁned by a Hematopoetic Cell
Transplantation Comorbidity Index (HCTCI) ≥3, median
OS after administration of intensive chemotherapy is shown
to be similar to the OS observed when only low dose
cytarabine is oﬀered [27]. Accordingly, the NCCN guidelines
recommend low-intensity therapy or palliation only for
older AML patients with an ECOG score >2[ 18]. In the
same vein, the Italian Society of Hematology guidelines
recommends best supportive therapy in patients older than
80 years or with severe comorbidities or with poor and
not potentially reversible performance status [19]. In elderly
patients with preserved organ function and performance
status, palliation is probably not a reasonable option. The
European Organization for the Research and Treatment of
Cancer (EORTC) formally compared in ambulatory patients
older than 65 years intensive induction chemotherapy
(daunorubicin 30mg/m2 for 3 days, cytarabine 100mg/m2
for 7 days and vincristine 2mg) versus a “wait and see”
strategy until disease progression followed by palliative
therapy with hydroxyurea and subcutaneous aracytin [28].
The median survival was signiﬁcantly longer in the inten-
sive chemotherapy arm (21 weeks versus 11 weeks) and
chemotherapy-treated older patients had a higher chance
of survival at 2.5 years (17% versus 0% in the palliative
arm). Unexpectedly, there was no diﬀerence in days spent in
hospital between the two arms. However, this was a small
randomized study (31 patients in the chemotherapy arm
and 29 in the observation/palliation arm), it was conducted
about 20 years ago and in the meanwhile only single-
institution or single hospital registry studies addressed the
same issues. Recently, a retrospective study by the Swedish
national acute leukemia registry compared early death rates,
CR rates and overall survival in AML patients aged 70–
79 years old from 6 distinct Swedish healthcare regions,
which diﬀer according to the therapeutic strategy applied in
this elderly patient cohort (distinct proportion of patients
oﬀered intensive chemotherapy versus supportive care in
each healthcare region) [29]. This study showed improved
overall survival in the regions where more AML patients
were given intensive treatment and suggested that standard
intensive treatment decreases rather than increases early
death rates and improves long term survival compared with
palliation in elderly patients up to 80 years [29]. These
results as well as the results from the EORTC study obviously
do not aim to propose standard intensive chemotherapy in
elderly AML as a satisfactory therapy. However, they show
that standard induction chemotherapy is clearly superior
to palliative care for the majority of elderly AML patients,
thus putting into question the consistent proportion of
elderlyAMLgivenonlysupportivetherapyincurrentclinical
practice.
3.2. Attempts to Identify the Optimal Induction Chemotherapy
Regimen. Considering the disappointing results of standard
chemotherapy in elderly AML, a number of groups have
evaluated or are currently evaluating various strategies
in investigational trials in order to improve outcome.
Attempts have been made in order to develop more eﬀective
chemotherapeutic regimens with improved tolerability and
to reduce drug resistance.
3.2.1. Attempts to Optimize the Standard Induction Regimen.
In the beginning, many study groups tried to identify to
what extent intensive chemotherapy could and should be
performed in older adults with AML, and even if older
patientsshouldbetreatedsimilarlytoyoungerAMLpatients.
Varying dose intensities of ARA-C and daunorubicin were
tested so as to optimize the risk/beneﬁt ratio. Two large
multicenter studies performed in England (MRC) and in
Germany (AMLCG) reported a signiﬁcant improvement of
survival from full (50–60mg/m2/day) dose versus attenuated
dose (30mg/m2/day) daunorubicin without the expense of
an increased rate of mortality [30, 31]. More recently, a
further escalation of the dose of daunorubicin in elderly
AML patients to twice the conventional dose (90mg/m2)
showed that in the age group of 60–65 years old the
escalated dose of daunorubicin results in improved complete
remission,event—freeandoverallsurvivalratesascompared
to standard dose daunorubicin (45mg/m2) without addi-
tional toxic eﬀects [32]. Whereas these data demonstrate the
importance of intensity and indicate that age should not
be a factor for reduction of the anthracyclin dose, this is
not the case for cytarabine. Separate randomized trials have
found that high dose cytarabine (2-3g/m2)f a i l e dt oi m p r o v e
survival or CR rate in older patients and often produced
toxicity,particularlyneurotoxicity[33–35].Therefore,unlike
in younger patients, high dose Ara-C should be omitted in4 Journal of Oncology
the elderly. Initial reports favoured idarubicin as the best
anthracycline to be given in conjunction with cytarabine in
the elderly [36]. However, further randomised studies found
no diﬀerence in long-term outcome between idarubicin,
daunorubicin or the anthrachinon derivative mitoxantrone
[37]. Other drugs that have been evaluated in elderly AML
include 6-thioguanine, etoposide, or ﬂudarabine, mostly in
conjunction with an anthracycline derivate and/or cytara-
bine [37]. Unfortunately, in these studies none of the above
regimens seem to oﬀer any substantial survival advantage
over the standard regimen [37].
3.2.2. Attempts to Improve Tolerability of the Induction
Chemotherapy. The hematopoietic growth factors granu-
locyte macrophage colony stimulating factor (GM-CSF)
and granulocyte colony simulating factor (G-CSF) have
been used either to shorten the duration of neutropenia
after chemotherapy, or to “prime” leukemic cells so that
chemotherapeutic agents might be more eﬀective. The
concept of G-SCF priming in AML was based on preclinical
studies suggesting that G-SCF and GM-SCF administered
prior to chemotherapy induce proliferation of AML cells
which sensitizes them to cell cycle–speciﬁc agents, as cytara-
bine [38]. However, a number of clinical trials examining
the impact of growth factors administration in elderly AML
patients either prior or after chemotherapy did not show
any beneﬁt regarding overall survival [39–42]. Nonetheless,
the published data support that growth factors’ use is safe
[39–41], suggesting that their routine use probably rests
on economic factors, which is the balance between G-
SCF treatment cost and potential G-CSF related decline in
hospitalization days.
Recently, the “priming” concept in AML is reinforced by
preclinical studies showing that the SDF-1 inhibitor Pler-
ixafor (AMD3100), clinically developed as a mobilization
agent for hematopoietic stem cell transplantation (HCT),
sensitizes AML blasts to the eﬀects of chemotherapy due
to disruption of their interaction with the bone marrow
microenviroment [43]. Results from a phase I/II study eval-
uating Plerixafor (80, 160 and 240mcg/kg) prior to salvage
chemotherapy in relapsed and refractory AML patients were
encouraging, with a CR achieved in 6 out of 8 evaluable
patients with no evidence of toxicity [44]. Ongoing clinical
trials are evaluating the safety and eﬃcacy of plerixafor as a
priming agent in AML.
3.2.3.AttemptstoReverseDrugResistance. Oneoftheadverse
biologic features of elderly AML as compared to younger
patients is the more frequent expression of P-glycoprotein,
an energy-dependent pump eﬄuxing cytotoxic drugs out of
the cell [8]. One strategy to reverse drug resistance that has
undergone signiﬁcant testing in older adults is the adjunctive
useinstandardinductionchemotherapyofagentsthoughtto
inhibit P-gP, leading in this way to increased cytotoxic drug
retention [37]. Two studies evaluating induction chemother-
apy with or without cyclosporine in poor risk AML patients
suggested a potential beneﬁt of P-gP modulation in these
patients [45, 46]. However, clinical trials evaluating the
eﬃcacy of a speciﬁc MDR-1 inhibitor PSC-833 (Valspodar)
both in younger and elderly AML patients were negative
[47–49]. In addition, the more speciﬁc MDR-1 inhibitor
Zosuquidar was tested in elderly (>60 years) AML patients
with standard 3 + 7 induction without any clear beneﬁt [50].
The multiple negative large randomized studies of MRD1
inhibitors in combination with induction chemotherapy in
AML so far are discouraging regarding the eﬃcacy of these
agents in AML treatment.
4.AlternativeTreatmentApproaches
in Elderly AML
As older adults with AML are either judged as “unﬁt”
or do poorly with standard induction chemotherapy, this
patient population has created an opportunity to study
novel, investigational therapies. However, the decision to
oﬀer an older AML patient an investigational therapy should
not be based on the promise of the new therapy but on
the assessment that, according to the risk stratiﬁcation
and the performance status of the patient, the outcome
of standard therapy will be disappointing [5]. A number
of novel approaches have entered clinical trials within the
last years. There are several new treatment strategies under
development, some more and others less toxic:
4.1. New Chemotherapies. Clofarabine is a new-generation
purinenucleosideanaloguewhichisdesignedtocombinethe
most favorable pharmacokinetic properties of ﬂudarabine
with a less toxic proﬁle [11]. Clofarabine seems to have a
signiﬁcant activity in untreated older adults (>70 years),
including those patients with adverse cytogenetics [51,
52]. In particular, clofarabine (30mg/m2 for 5 consecutive
days repeated every 28 days) was tested in elderly AML
patients(>65years)considered“unﬁt”forstandardintensive
chemotherapy in a phase II nonrandomized study (BIOV-
121) [51]. 25% of these patients had unfavourable cytoge-
netics whereas 55% of patients were >70 years. The overall
response rate (ORR) in the unfavourable cytogenetic group
was 36% with CR = 27%, while in patients >70 years
the ORR and CR rates were 56% and 44%, respectively.
Another phase II study evaluating single agent clofarabine
(30mg/m2on days 1–5) in 109 previously untreated elderly
(>60 years) patients with ≥1 adverse features (high risk
cytogenetics, AHD, PS > 2, age >70 years) reported an ORR
of 58% in the unfavourable cytogenetic group and 44% in
the group with AHD [52]. Further, clofarabine has been
tested in combination with low dose cytarabine in previously
untreated patients with AML aged 60 years and older. The
combination showed a higher CR rate than clofarabine alone
(63% versus 31%) with comparable toxicity [53].
Cloretazine is a novel DNA alkylating agent selectively
targeting the O-6 position in guanine, which is shown to
have a signiﬁcant activity in elderly de novo AML [54]
Cloretazine was evaluated as single agent therapy in elderly
patients (>60 years) with poor risk AML or high risk
MDS [54] .T h eC Rr a t ei nd en o v oA M Lw a s4 9 %a n d
unexpectedly comparable in the intermediate (50%) and
adverse cytogenetics cohort (53%). However, an early deathJournal of Oncology 5
rate of 20% was reported. In a multicenter phase II study
a single intravenous infusion of cloretazine (600mg/m2)
was tested in 104 previously untreated elderly (>60 years)
AML patients [55]. Importantly, no patient had a favorable
karyotype whereas a signiﬁcant cohort of patient had
comorbid disease: PS = 2 (30%), pre-existing cardiac disease
(45%), and pre-existing hepatic disease (24%). Despite this,
ORR was 50% in de novo versus 11% in secondary AML.
Responsebycytogenetic risk categorywas39% in 56patients
with intermediate cytogenetic risk and 24% in 46 patients
with unfavorable cytogenetic risk. An early death rate of 18%
was reported. Further studies are evaluating the eﬃcacy and
toxicity of cloretazine in elderly poor risk AML patients.
Aberrant hypermethylation and silencing of genes
involved in cell proliferation and diﬀerentiation are com-
monly found in AML [56]. Therefore, hypomethylating
agents may exert antineoplastic activity as inducers of
diﬀerentiation or response modiﬁers. 5-azacitidine was
approved in 2004 for the treatment of all subtypes of MDS
(75mg/m2 given subcutaneously for 7 consecutive days at a
21 days interval) [57, 58]. Recently, the eﬃcacy of azacitidine
was compared to conventional care regimens (CCR: best
supportive care, low dose cytarabin or standard induction
chemotherapy) in a phase III study in 358 patients with
higher risk MDS (median age = 69 years) [59]. Interestingly,
almost one third of the patients (113 of 358) met the
WHO criteria for AML (median bone marrow blasts 23%).
Analysis of this patient’ subset showed a median overall
survival of 24.5 months in the 5-azacitidine arm versus 16
months with conventional care regimens. In addition, 50%
of patients treated with 5-azacitidine survived for two years
as compared to only 16% of patients treated with CCR. Most
common side eﬀects were thrombocytopenia, neutropenia
and anemia. These results suggest that the probable survival
beneﬁtof5-azacitidineinMDSmayextendtoAMLpatients.
More recently, the eﬃcacy of azacytidine was shown in 81
MDS/AML patients with chromosome 5 or 7 abnormalities
[60].41%patientstreatedwithazacitidineachievedCR,with
a median CR duration of 45 weeks. Interestingly, in this sin-
gle institution study treatment with hypomethylating agents
seemed to be superior to chemotherapy [60]. Decitabine is
another hypomethylating agent which has been evaluated in
AML. A phase II study evaluated the eﬃcacy of low dose
decitabine (135mg/m2 repeated every 6 weeks for up to 4
courses) in elderly AML patients (>60 years) not qualifying
for, or not consenting to standard induction treatment [61].
So far, results from 278 fully evaluable patients have been
reported. Complete and partial remissions occurred in 25%
of patients, an antileukemic eﬀect in another 29% whereas
early death rate was 13%.
4.2. Antibody Targeted Therapies. The surface molecule
CD33 is expressed on leukemic blasts of most patients with
AML [11]. Gemtuzumab ozogamicin (GO, Mylotarg) is a
humanised anti-CD33 antibody linked to a highly potent
toxin and is approved since 2001 as the ﬁrst agent speciﬁcally
for use in treating older adults with AML (single agent
treatment in AML patients ≥60 years at ﬁrst relapse who
are not ﬁt for other cytotoxic therapy) [11]. The approved
dose is 9mg/m2 g i v e no nd a y s1a n d1 5[ 11]. Final results
of three multicentre open-label single arm phase II studies
evaluating GO as monotherapy in the treatment of 277 AML
patients atﬁrstrelapsehavebeenrecentlyreported[62].57%
of patients were 60 years or older. Patients were scheduled to
receive 2 doses of GO (9mg/m2) in a 14–28 days interval.
Overall remission in the elderly population was 26%, with
CR = 13% and complete response with incomplete platelet
recovery (CRp) 13%. Importantly, there were no diﬀerences
in response rates among patients stratiﬁed by cytogenetic
abnormalities. Elderly patients who achieved CR or CRp had
a median overall survival of 11.7 months and 11.4 months,
respectively. Grade III or IV neutropenia was a universal
side eﬀect observed in 98% of patients; however, sepsis
occurred in 18% and pneumonia in 8%. Early death rate
in the elderly population was 17%. A neutrophil recovery
deﬁned as ≥500/L was observed in a median of 40 days,
43 days, and 51 days from the ﬁrst dose of GO in the CR,
CRp, and no response arms respectively. Other side eﬀects
included liver function abnormalities, mostly transient and
reversible elevations of bilirubin (≥1.5 of the upper limit
of normal), whereas 0.9% of patients who received GO and
did not undergo prior or subsequent hematopoetic stem
cell transplantation developed venoocclusive disease (VOD).
Lower dose GO is also being evaluated in relapsed elderly
AML in combination with other agents. In this vein, GO
(6mg/m2 on day 1 and 4mg/m2 on day 8) and cytarabine
(100mg/m2/24hr on days 1–7) were evaluated in fourteen
elderly AML patients with relapsed or secondary AML [63].
Overall response rate was 28%, with two patients achieving
CR, one CRp and one partial response (PR). TRM was
28%. In another study 53 elderly patients with poor risk
AML(untreatedorrelapsed/primaryrefractory)weretreated
with a combination of GO (6mg/m2 on day 9), cytarabin
(100mg/m2/24hr on days 2–8) and G-CSF (rhG-CSF 5lg/kg
ondays1–8);thecombinationcalledG-AraMyregimen[64].
The overall response rate was 57% with CR = 43%, CRp =
2% and PR = 21%.
Further, GO is evaluated as front-line therapy in elderly
AML. A study by the GIMEMA/EORTC group evaluated
GO (9mg/m2, d1 and d15) in combination with cytotoxic
chemotherapy(MICE:mitoxandrone,cytarabine,etoposide)
as front line treatment in 57 patients 61–75 years with AML
[65]. ORR was 54.4% with CR achievement in 35.1% and
complete response with incomplete platelet recovery (CRp)
of 19.3%. The one year survival in this study was 34%, so
this regimen is now being evaluated in a phase III study
compared to conventional MICE regimen. Lower dose GO
(3mg/m2) has also been studied in combination with other
cytotoxic chemotherapies as front line therapy in elderly




inhibitor of the enzyme farnesyltrasferase, which modiﬁes
proteins for localization to cell membrane [11]. Given that
theactivityofcriticaloncoproteinsdependsonfarnesylation,
the eﬃcacy of tipifarnib as an antitumor agent has been6 Journal of Oncology
tested in several tumors, including AML. Although initial
results from phase I clinical trials were encouraging [11],
subsequent studies failed to show any beneﬁt of tipifarnib
treatment compared with palliative care in elderly AML
patients [68].
Given the adverse prognosis of FLT3 mutations in
younger AML patients, FLT3 inhibition is currently explored
as a therapeutic strategy in AML. Several agents with in
vitro activity in primary leukemic cells and in vivo activity
in rodent models, as lestaurtinib and midostaurin, are
evaluated as oral agents in clinical trials [69]. In contrast
to younger AML patients, FLT3 ITD do not appear to
correlate with an inferior clinical outcome in the elderly
patient population, however, a recent phase II trial tested
the oral FLT3 inhibitor lestaurtinib (CEP701) as ﬁrst-line
therapy in previously untreated older patients with AML
who were not “ﬁt” for intensive chemotherapy [69]. Toxicity
was limited and, although there were no CR’s, transient
reductions in bone marrow and peripheral-blood blasts or
longer periods of transfusion independence were observed.
FLT3 inhibitors are also being tested in combination with
standard chemotherapy.
5. Role of HCTin Elderly AML: Allogeneic
Hematopoietic CellTransplantationafter
Host-AdaptedConditioning
Allogeneic hematopoietic cell transplantation (allo-HCT)
can cure patients with myeloid malignancies, however,
increased age and frequent lack of sibling donors in older
patients discourages the transplantation choice. Therefore,
allo-HCT after conventional conditioning has been explored
only cautiously in selected older patients [70, 71]. New
transplant strategies which incorporate reduced intensity
conditioning (RIC) regimens have been established and have
been speciﬁcally attractive for patients of advanced age [72–
86]. Although a detailed discussion is beyond the scope of
this review, there are some interesting issues which we have
learned over the last years, and others, probably more, which
we still “don’t know” and are currently under evaluation.
(i) Allo-HCT in elderly is feasible. A numerous of
pilot studies have clearly demonstrated that the goal
of reducing transplant related mortality in older
patients by using RIC has been accomplished [72, 85,
86].
(ii) Eﬀectiveness. The eﬃcacy of RIC in allo-HCT for
elderly patients with AML has not been deﬁnitively
established because of a lack of controlled trials.
Although there are pilot trials reporting very good
outcomes in elderly AML patients, allo-HCT is often
criticized as being ineﬃcient. However, it must be
noticed that there is an overrepresentation of adverse
prognostic factors (e.g., complex caryotype, refrac-
tory disease etc.) in patients reported in small pilot
studiesexploringRIC,whichmightnegativelyimpact
any beneﬁt of allo-HCT in controlling leukemia. A
lot of variables, both patient as well as transplant
speciﬁc, may inﬂuence outcomes and therefore there
is an urgent need to deﬁne the optimal transplant
strategy in prospective controlled clinical trials.
(iii) Not all RIC regimens are the same [87]. There are a
numerous of RIC regimens which vary not only with
respect to dose intensity but also to the type of agents
u s e d .S i n c ed o s ed o e sm a t t e r[ 88, 89], most protocols
are moving from the initially established “minimal
dose” concept with 2Gy TBI/ﬂudarabin [75, 78]t o
more intensive, while nontoxic, regimens (reduced
toxicityconditioning, RTC).Inthisvein,theaddition
of one or two alkylating agents in the conditioning
s e e m st ob em o r ee ﬀective in controlling leukemia
than truly nonmyeloablative ones [79, 84]. Novel
drugs like intravenous busulfan preparations [90],
treosulfan[91]orclofarabinearepromising agentsin
the ﬁeld of RIC. Another approach for maximal anti-
tumor activity with reduced toxicity is reported from
the Intermountain Blood and Marrow Transplant
Program (The LDS Hospital, Salt Lake City, Utah,
USA) [92] by using standard, dose-intense targeted
busulfan-cyclophosphamide regimen combined with
amaximalclinicalsupport.Largerandomizedstudies
comparing diﬀerent regimens are warranted.
(iv) Toxicity and eﬃcacy of a transplant strategy is
determined not only from the conditioning regimen
butalsofromtheestablishmentofthedonorimmune
system. A novel late-onset acute Graft versus Host
Disease (GvHD) occurring beyond the ﬁrst 3 months
has been observed in the clinical course of RIC [93].
The incorporation of in vivo anti T lymphocyte
sera in the conditioning regimen may reduce the
incidence of severe GvHD (which is a major concern
in the elderly), however, depending on the sera used
the risk of opportunistic infections increases.
(v) Sourceofstemcells.Althoughitwasinitially believed
that RIC should be only combined with peripheral
blood-derived grafts with their rich supply of eﬀector
cells, a recent EBMT retrospective study showed that
BM cells can be also used. Elderly patients have very
often similar aged siblings which counteract with
the safety of stem-cell donation. Nowadays, with
improved HLA matching at allele level and eﬃcient
GvHD prophylaxis protocols, results from unrelated
allogeneic HCT are as good as those after matched
sibling-HCT [84, 85, 94].
(vi) The issue as to whether patients with myeloid malig-
nancies, especially the older ones, should receive
remission induction chemotherapy before transplan-
tation is not clear. Studies in younger patients
with AML suggest that remission status at time of
transplantation has a major impact on outcome and
therefore a remission induction therapy should be
consideredbeforetransplantation[95].However,this
seems not to be the case in patients with secondary
AML or advanced MDS [96]. It appears that at least
for candidates with a smouldering increase of blastsJournal of Oncology 7
over time, transplantation with a myeloablative, high
antileukaemic, age-adapted regimen may be used as
front line therapy.
(vii) Epigenetic modulation in the allo-HCT setting.
Hypomethylating agents may be used prior to allo-
HCT for bridging the time to transplantation or
after transplantation either as maintance therapy
or to enhance graft versus leukemia (GvL) eﬀect
in combination with DLI. Preliminary results of
azacytidine given monthly after allo-HCT are very
promising [97, 98].
Taken together, age should not be the sole factor for dis-
qualifying a patient as transplant candidate. Some patients,
especially those with high risk features, are unprepared
to accept a maximal 15% chance of cure with intensive
chemotherapy and desire a treatment which has the highest
potential for achieving long term survival and cure. Every
patientwithAMLregardedasﬁtforinductionchemotherapy
and consented to intensive chemotherapy is also a candidate
for allogeneic HCT, should be informed about this treatment
option and be referred as early as possible to a transplant
center. Comorbidity indexes can help the physician to advice
between a transplant or no transplant decision [99].
6. Conclusions
AML reaches the highest frequency in the elderly and with
the aging of the general population in developed coun-
tries, the management of this disorder acquires increasing
importance.TheoptimaltreatmentdecisionforelderlyAML
patients remains a major challenge. The “3+7” regimen may
be considered standard therapy in older AML patients with
preserved performance status and a favorable or standard
risk karyotype, however, results remain far from being
satisfactory, whereas many older patients, especially those
with an unfavorable karyotype, are not beneﬁting at all from
this treatment. Therefore, the best option for elderly AML
patients is to be treated within controlled clinical trials.
Geriatric assessment tools can help the primary physician
with the decision between giving a palliative or curative
treatment. First results in allogeneic transplantation after
host adapted conditioning are very promising, and indicate
that age should not discourage transplantation as a choice.
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